Drug intelligence / Profile preview

Pingxiao Heji

Development stage: Preclinical
Administration: Oral

Overview

Pingxiao Heji (平哮合剂) is a Traditional Chinese Medicine (TCM) formula primarily investigated for its anti-asthma effects. Studies suggest it can reduce airway hyperresponsiveness and lower the levels of inflammatory mediators such as Interleukin-2 Receptor (IL-2R) and Interleukin-5 (IL-5), which are important in the pathogenesis of asthma. As a TCM, it is a combination of various natural ingredients, though the specific composition of this particular formula is not detailed in available research. It is used to alleviate symptoms associated with asthma by modulating inflammatory responses and improving airway function.

Other names: 平哮合剂

Targets

IL-5 (Interleukin 5)IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on Pingxiao Heji.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pingxiao Heji.

Explore the full profile